



Cohere Medical Policy – Magnetic Resonance Imaging (MRI), Abdomen and Magnetic Resonance Cholangiopancreatography (MRCP)

Clinical Guidelines for Medical Necessity Review

Version: 3
Revision Date: February 20, 2025

Important Notices

Notices & Disclaimers:

GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2025 Cohere Health, Inc. All Rights Reserved.

Other Notices:

HCPCS® and CPT® copyright 2025 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

Guideline Information:

Specialty Area: Diagnostic Imaging

Guideline Name: Cohere Medical Policy - Magnetic Resonance Imaging (MRI), Abdomen and Magnetic Resonance Cholangiopancreatography (MRCP)

Date of last literature review: 7/31/2024

Document last updated: 2/19/25

Type: Adult (18+ yo) | Pediatric (0-17yo)

Table of Contents

Important Notices	2
Medical Necessity Criteria	4
Service: Magnetic Resonance Imaging (MRI), Abdomen and Magnetic Resonance Cholangiopancreatography (MRCP)	4
Recommended Clinical Approach	4
Medical Necessity Criteria	4
Indications	4
Non-Indications	12
Level of Care Criteria	12
Procedure Codes (CPT/HCPCS)	12
Medical Evidence	14
References	16
Clinical Guideline Revision History/Information	22

Medical Necessity Criteria

Service: Magnetic Resonance Imaging (MRI), Abdomen and Magnetic Resonance Cholangiopancreatography (MRCP)

Recommended Clinical Approach

The use of contrast and the type of magnetic resonance (MR) contrast (e.g., extracellular or hepatobiliary-specific) should be at the request of the ordering provider with guidance from the radiologist. The MR field of view should be limited to the area of interest and, in some cases, may not be the preferred imaging study.

Medical Necessity Criteria

Indications

→ **Magnetic resonance imaging (MRI), abdomen** is considered appropriate if **ALL** of the following are **TRUE**¹:

◆ **ANY** of the following:

- Ultrasound or CT/CTA are contraindicated or inconclusive (e.g., body habitus for ultrasound, anaphylactic reaction due to IV contrast reaction, pregnancy, pediatric); **OR**
- Radiology/ordering provider recommends MRI as optimal imaging modality for specific clinical case; **AND**

◆ **ANY** of the following:

- Suspected appendicitis in a pregnant patient; **OR**
- Suspected appendicitis in a pediatric patient; **OR**
- Unexplained abdominal pain in a pregnant person or pediatric patient with non-diagnostic ultrasound; **OR**
- Suspected abdominal abscess, diverticulitis, complicated UTI in a pregnant person or pediatric patient; **OR**

- Detection, screening, surveillance, and follow-up of malignancies or metastatic involvement in the abdomen for **ANY** of the following²⁻⁴:
 - To further characterize a lesion previously identified on another imaging study when that imaging study is inconclusive; **OR**
 - Metastases, known or suspected, including preoperative mapping for liver resection; **OR**
 - Known or suspected primary malignancies with an assessment of vascular and biliary invasion, including but not limited to **ANY** of the following⁵:
 - ◆ Rising alpha-fetoprotein (AFP) in a high-risk patient or patient with known hepatocellular carcinoma (HCC); **OR**
 - ◆ CA 19-9; **OR**
 - ◆ Painless jaundice; **OR**
 - ◆ Persistent hematuria; **OR**
 - ◆ Other biomarker/sign/symptom suggestive of underlying malignancy; **OR**
 - Tumor response to treatment (e.g., image-guided liver interventions or tumor ablation, chemoembolization, radioembolization, chemotherapy, radiotherapy, surgery)⁶; **OR**
 - Annual screening of a patient with an increased risk of cancer due to **ANY** of the following:
 - ◆ Cirrhosis or chronic viral hepatitis where ultrasound or CT is nondiagnostic; **OR**
 - ◆ Primary sclerosing cholangitis after age 20⁷; **OR**

- ◆ Known mutation that increases susceptibility (e.g., Von Hippel Lindai, Tuberous Sclerosis, BRCA-1/2); **OR**
- ◆ The patient has two or more first-degree or second-degree relatives with the same or related cancer on the same side of the family; **OR**
- For evaluation of known benign or indeterminate adrenal masses with **ANY** of the following⁸⁻⁹:
 - Indeterminate adrenal mass found on initial imaging, and **ANY** of the following:
 - ◆ 1-4 cm with follow-up at 6-12 months¹⁰; **OR**
 - ◆ Potential metastatic involvement and less than 4 cm; **OR**
 - Adrenal adenoma, known or suspected based on clinical **AND** laboratory findings; **OR**
- Abdominal wall abnormalities, including hernias¹¹; **OR**
- Peritoneal or mesenteric abnormalities such as carcinomatosis, internal hernias, or infarct; **OR**
- Characterization and follow-up of intra-abdominal fluid collections; **OR**
- Gastrointestinal tract evaluation, as indicated by **ANY** of the following¹²:
 - Celiac disease with recurring symptoms despite maintaining a gluten-free diet for 12 months or more¹³; **OR**
 - Crohn's disease, known or suspected¹⁴; **OR**
 - Other autoimmune enteritis with small bowel involvement; **OR**
 - Volvulus, internal hernias, incarceration; **OR**

- Hepatobiliary system (liver, bile ducts, gallbladder, and associated structures) as indicated by **ANY** of the following⁶:
 - To further characterize a lesion previously identified on ultrasound or CT scan when the CT/ultrasound result is inconclusive; **OR**
 - Infection/inflammation (e.g. cholangitis)⁶; **OR**
 - Autoimmune (e.g., autoimmune hepatitis, primary biliary cirrhosis); **OR**
 - Pre-operative or post-operative evaluation (e.g., liver resection, donor or transplant, hepatic shunt placement); **OR**
 - Non-invasive quantification of iron, fat, and fibrosis in chronic liver disease (e.g., hemochromatosis, hemosiderosis, nonalcoholic steatohepatitis [NASH] hepatitis), includes hepatic elastography; **OR**
 - Gallbladder disease, including evaluation of indeterminate polyps/nodules detected with other imaging modalities¹⁵; **OR**
- Kidney and urinary system disease as indicated by **ANY** of the following¹⁶⁻¹⁹:
 - Surveillance of renal cysts with classification of Bosniak IIF or above; **OR**
 - Solid or complex cystic renal mass; **OR**
 - Annual evaluation of asymptomatic renal angiomyolipomas smaller than 4 cm⁴⁴; **OR**
 - Symptomatic renal angiomyolipoma of any size⁴⁴; **OR**
 - Characterization of other indeterminate lesions detected with other imaging modalities; **OR**

- Diagnostic evaluation of concerning signs/symptoms (e.g., pain, concern for rupture, infection, hemorrhage) in a patient with known polycystic kidney disease²⁰; **OR**
- Infectious or inflammatory disease (e.g., complicated pyelonephritis); **OR**
- Anatomic abnormalities, congenital or acquired (e.g., horseshoe kidney, retroperitoneal fibrosis); **OR**
- Evaluation of the ureters/collecting system (e.g., stones, tumors, or stricture); **OR**
- Pancreatic abnormalities as indicated by **ANY** of the following²¹:
 - Duct anomaly²²; **OR**
 - Duct obstruction (e.g., calculi, stricture, or mass)²²; **OR**
 - Fluid collections; **OR**
 - Pancreatic pseudocysts; **OR**
 - Indeterminate lesions; **OR**
 - Pancreatitis (acute or chronic) with **ANY** of the following²³⁻²⁴:
 - ◆ Concern for complications such as necrosis or abscess; **OR**
 - ◆ Lack of response to conservative treatment and management; **OR**
 - ◆ Ultrasound or other imaging study did not show clear etiology, such as a stone; **OR**
 - Indeterminate cyst in an asymptomatic patient that requires follow-up, and **ANY** of the following is **TRUE**^{22,25}:
 - ◆ One-year follow-up imaging when interval growth is present on the previous follow-up; **OR**

- ◆ The cyst is less than 1.5 cm without interval growth, and **ANY** of the following is **TRUE**:
 - For patients less than 65 years of age, annually up to five years; **OR**
 - For patients from 65 to 79 years of age, every two years up to ten years; **OR**
 - For patients more than 80 years of age, every two years up to four years; **OR**
- ◆ Cyst is greater than 1.5 cm without interval growth, and **ANY** of the following is **TRUE** :
 - The patient is less than 80 years old, and **ANY** of the following frequency limitations is **TRUE**:
 - Up to every 6 months for 2 years from diagnosis; **OR**
 - Up to annually for up to ten years from diagnosis; **OR**
 - The patient is greater or equal to 80 years old with a frequency limitation of every 2 years for 4 years; **OR**
- Splenic abnormalities as indicated by **ANY** of the following:
 - ◆ Characterization of indeterminate lesions detected with other imaging modalities; **OR**
 - ◆ Detection and characterization of suspected diffuse abnormalities of the spleen; **OR**
- Post-traumatic organ injury; **OR**
- Fever of unknown origin greater than 101°F for at least 3 weeks where laboratory and clinical workup have been performed and have not revealed a diagnosis²⁶⁻²⁷; **OR**

- Preoperative, postoperative, or pre-treatment evaluation for **ANY** of the following:
 - Post-surgical complications involving the hepatobiliary system (bile ducts, gallbladder, and associated structures)⁶; **OR**
 - Post-treatment follow-up for **ANY** of the following:
 - ◆ Complications of pancreatitis; **OR**
 - ◆ Fluid collections; **OR**
 - ◆ Pancreatic duct anomalies; **OR**
- Characterization of complex congenital anomalies (e.g., genitourinary and pelvic organs)¹⁶⁻¹⁹; **OR**
- Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality) in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following are true:
 - New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
 - One-time clarifying follow-up of a prior indeterminate finding; **OR**
 - In the absence of change in symptoms, there is an established need for monitoring which would influence management; **OR**

→ **Magnetic resonance cholangiopancreatography (MRCP)** is considered appropriate if **ANY** of the following is **TRUE**:

- ◆ The patient has **ANY** of the following:
 - Evidence of biliary obstruction or involvement, including **ANY** of the following²⁸⁻³⁰:
 - Biliary duct dilation requiring further work-up; **OR**
 - Jaundice³¹; **OR**

- Laboratory or biochemical markers, including increased alkaline phosphatase, gamma-glutamyl transpeptidase, or conjugated (direct) bilirubinemia; **OR**
- Known or suspected abnormalities of the pancreatic and biliary ducts, including **ANY** of the following^{28-29,32-33}:
 - Acute pancreatitis³⁴; **OR**
 - Chronic pancreatitis³⁴; **OR**
 - Cystic lesions in the pancreas²²; **OR**
 - Ductal stones; **OR**
 - Evaluation of bile duct dilation or stricture; **OR**
- Unexplained right upper quadrant pain^{15,28-29}; **OR**
- ◆ Assessment of post-liver transplant biliary complications; **OR**
- ◆ When ERCP is unsuccessful or contraindicated, or therapeutic ERCP is unlikely to be needed^{11,28-29,35}; **OR**
- ◆ Delineation of ductal anatomy before liver transplantation; **OR**
- ◆ Detection and anatomic delineation of bile leaks; **OR**
- ◆ Detection, staging, and post-treatment follow-up of bile duct and gallbladder cancer; **OR**
- ◆ Evaluation of suspected congenital abnormalities of the gallbladder or bile ducts; **OR**
- ◆ Follow-up after surgery or intervention; **OR**
- ◆ Repeat imaging (defined as repeat request following recent imaging of the same anatomic region with the same modality) in the absence of established guidelines, will be considered reasonable and necessary if **ANY** of the following are true:
 - New or worsening symptoms, such that repeat imaging would influence treatment; **OR**
 - One-time clarifying follow-up of a prior indeterminate finding; **OR**

- In the absence of change in symptoms, there is an established need for monitoring which would influence management.

Non-Indications

→ **Magnetic resonance imaging (MRI), abdomen or magnetic resonance cholangiopancreatography (MRCP)** are not considered appropriate if **ANY** of the following is **TRUE**:

- ◆ The patient has undergone advanced imaging of the same body part within 3 months without undergoing treatment or developing new or worsening symptoms³⁶; **OR**
- ◆ If contrast is used, history of anaphylactic allergic reaction to gadolinium contrast media with detailed guidelines for use in patients with renal insufficiency; **OR**
- ◆ The patient has metallic clips on vascular aneurysms; **OR**
- ◆ Incompatible implantable devices (e.g., pacemakers, defibrillators, cardiac valves); **OR**
- ◆ Metallic foreign body in orbits/other critical area(s) or within the field of view and obscuring area of concern; **OR**
- ◆ Benign prostatic hyperplasia (BPH), initial or follow-up imaging.³⁷

*NOTE: MRI in patients with claustrophobia should be requested at the discretion of the ordering provider.

**NOTE: MRI in pregnant patients should be requested at the discretion of the ordering provider and obstetric care provider.

Level of Care Criteria

Inpatient or Outpatient

Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
----------------	------------------

74181	Magnetic resonance imaging (MRI) (e.g., proton), abdomen; without contrast material(s)
74182	Magnetic resonance imaging (MRI) (e.g., proton), abdomen; with contrast material(s)
74183	Magnetic resonance imaging (MRI) (e.g., proton), abdomen, without contrast material(s), followed by contrast material(s) and further sequences
S8037	Magnetic resonance cholangiopancreatography (MRCP)

Medical Evidence

Hernando et al. (2022) reviewed quantitative diffusion MRI of the abdomen and pelvis, which involves employing multiple diffusion encodings and mapping diffusion parameters. Diffusion MRI allows the ability to gauge tissue microstructure sensitivity. In contrast to qualitative diffusion-weighted MRI, the quantitative approach enhances the standardization of tissue characterization, which is crucial for disease detection, staging, and treatment monitoring. Challenges include acquisition artifacts, limitations in signal modeling, and biological variability. Technical performance concerns include addressing physiologic motion (respiratory, peristaltic, and pulsatile), handling image distortions, and managing a low signal-to-noise ratio.³⁸

The American Urological Association (AUA) published guidelines on renal mass and localized renal cancer. Based on recommendations from the American College of Radiology (ACR), cross-sectional nervous system imaging is the preferred diagnostic method for identifying or ruling out metastases in the brain and spine. While MRI may exhibit greater sensitivity in detecting small central nervous system (CNS) neoplasms, CT can be beneficial for promptly assessing acute neurological signs or symptoms. MRI benefits patients who cannot receive IV iodinated contrast before and after administering gadolinium. Cross-sectional MRI with diffusion-weighted imaging benefits for patients who cannot tolerate conventional contrast. If there is suspicion of a mass, contrast-enhanced ultrasound can be employed to assess for enhancement.¹⁸⁻¹⁹

Staubli et al. (2022) performed a randomized control trial (RCT) comparing intraoperative cholangiography (IOC) and magnetic resonance cholangiopancreatography (MRCP) in patients suspected of having common bile duct stones (CBDS). It was a multicenter randomized controlled trial conducted across five hospitals. Patients were randomly assigned to receive either IOC followed by laparoscopic cholecystectomy (LC) with potential endoscopic retrograde cholangiopancreatography (ERCP) or MRCP followed by ERCP and LC if deemed necessary. The primary focus was on the LOS, with secondary measures encompassing cost, stone detection, and complication

rates. The findings indicated that IOC was more effective in diagnosing CBDS than MRCP. Although the median LOS was slightly shorter in the IOC group, this variance did not reach statistical significance. No significant cost difference was observed between the two approaches. However, CBDS were more frequently detected in the IOC group. Complication rates did not exhibit disparity between the two methods. The study concluded that while IOC and MRCP are viable options, IOC stands out for its notably higher diagnostic yield in detecting CBDS. (Clinicaltrials.gov Identifier: NCT02351492).³⁹

Suzuki et al. conducted an RCT to evaluate the diagnostic precision of endoscopic ultrasound (EUS) and MRCP in detecting choledocholithiasis cases initially overlooked on CT scans. Patients suspected of having CBDS were divided into two groups: one receiving EUS and the other MRCP. Initially, those diagnosed with CBDS or sludge underwent ERCP, while CBDS-negative patients underwent a second diagnostic procedure, either MRCP or EUS, different from the initial one. The main focus was on the accuracy of diagnosis, with secondary interests in diagnostic capabilities, CBDS detection rates and characteristics during the second examination, and adverse event occurrence. Overall, EUS may provide higher diagnostic ability than MRCP; however, the authors did not note significant differences in recommending one procedure over the other.⁴⁰

Timmerhuis et al. (2021) performed a systematic review of available guidelines for diagnosing a disrupted pancreatic duct in patients with acute pancreatitis. Eight studies with five distinct diagnostic modalities in 142 severe acute pancreatitis patients were included. Endoscopic ultrasound and ERCP reported a sensitivity of 100%. A sensitivity of 83% was reported with MRCP, with or without secretin. A combined cohort of secretin-enhanced MRCP and standard MRCP showed a sensitivity of 92%. Amylase measurements in drain fluid exhibited a sensitivity of 100% and specificity of 50% compared to ERCP. The authors concluded that various diagnostic modalities effectively diagnose disrupted pancreatic ducts in acute pancreatitis patients. Considering the invasiveness of alternative modalities, secretin-enhanced MRCP is recommended as the initial diagnostic approach.⁴¹

References

1. American College of Radiology (ACR). ACR practice parameter for performing and interpreting magnetic resonance imaging (MRI) (resolution 8). Updated 2022. Accessed June 5, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Perf-Interpret.pdf>.
2. Expert Panel on Urological Imaging, Purysko AS, Nikolaidis P, et al. ACR appropriateness criteria – post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma. Updated 2022. Accessed June 5, 2024. <https://acsearch.acr.org/docs/69365/Narrative/>.
3. Expert Panel on Urological Imaging, Ganeshan D, Khatri G, et al. ACR appropriateness criteria – staging of renal cell carcinoma. Updated 2022. Accessed June 5, 2024. <https://acsearch.acr.org/docs/69372/Narrative/>.
4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Wilms tumor (nephroblastoma) (ver. 1.2023). Published March 14, 2023. Accessed June 5, 2024. https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf.
5. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Pancreatic adenocarcinoma (ver. 1.2024). Published December 13, 2023. Accessed June 5, 2024. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
6. American College of Radiology (ACR). ACR–SAR–SPR practice parameter for the performance of magnetic resonance imaging (MRI) of the liver (resolution 27). Updated 2020. Accessed June 5, 2024. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Liver.pdf>.
7. Bowlus CL, Lim JK, Lindor KD. AGA clinical practice update on surveillance for hepatobiliary: Cancers in patients with primary sclerosing cholangitis: Expert review. *Clin Gastroenterol Hepatol*. Nov 2019;17(12):2416–2422. doi: 10.1016/j.cgh.2019.07.011.
8. Expert Panel on Urological Imaging, Mody RN, Remer EM, et al. ACR appropriateness criteria – adrenal mass evaluation: 2021 update. *J Am*

- Coll Radiol.* 2021 Nov;18(11S):S251–S267. doi: 10.1016/j.jacr.2021.08.010. PMID: 34794587.
9. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Neuroendocrine and adrenal tumors (ver. 1.2023). Published August 2, 2023. Accessed June 5, 2024. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.
 10. Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons Guidelines for adrenalectomy: Executive summary. *JAMA Surg.* 2022 Oct 1;157(10):870–877. doi: 10.1001/jamasurg.2022.3544. PMID: 35976622; PMCID: PMC9386598.
 11. Expert Panel on Gastrointestinal Imaging, Garcia EM, Pietryga JA, et al. ACR appropriateness criteria – hernia. *J Am Coll Radiol.* 2022 Nov;19(11S):S329–S340. doi: 10.1016/j.jacr.2022.09.016. PMID: 36436960.
 12. Expert Panel on Musculoskeletal Imaging, Garner HW, Wessell DE, et al. ACR appropriateness criteria – soft tissue masses. Published 2022. Accessed June 5, 2024. <https://acsearch.acr.org/docs/69434/Narrative/>.
 13. Green PHR, Paski S, Ko CW, et al. AGA clinical practice update on management of refractory celiac disease: Expert review. *Gastroenterology.* 2022 Nov;163(5):1461–1469. doi: 10.1053/j.gastro.2022.07.086. PMID: 36137844.
 14. Expert Panel on Gastrointestinal Imaging, Kim DH, Chang KJ, et al. ACR appropriateness criteria – Crohn disease. *J Am Coll Radiol.* 2020 May;17(5S):S81–S99. doi: 10.1016/j.jacr.2020.01.030. PMID: 32370980.
 15. Expert Panel on Musculoskeletal Imaging, Russo GK, Zaheer A, et al. ACR appropriateness criteria – right upper quadrant pain. Updated 2022. Accessed June 5, 2024. <https://acsearch.acr.org/docs/69474/Narrative/>.
 16. Expert Panel on Urological Imaging, Wang ZJ, Nikolaidis P, et al. ACR appropriateness criteria – indeterminate renal mass. Updated 2020. Accessed June 5, 2024. <https://acsearch.acr.org/docs/69367/Narrative/>.
 17. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Kidney cancer (ver. 2.2024). Published

January 3, 2024. Accessed June 5, 2024.

https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

18. Campbell SC, Clark PE, Chang SS, et al. Renal mass and localized renal cancer: Evaluation, management, and follow-up: AUA Guideline: Part I. *J Urol*. 2021 Aug;206(2):199–208. doi: 10.1097/JU.0000000000001911. PMID: 34115547.
19. Campbell SC, Uzzo RG, Karam JA, et al. Renal mass and localized renal cancer: Evaluation, management, and follow-up: AUA Guideline: Part II. *J Urol*. 2021 Aug;206(2):209–218. doi: 10.1097/JU.0000000000001912. PMID: 34115531.
20. Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. *Nat Rev Dis Primers*. 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y. PMID: 30523303; PMCID: PMC6592047.
21. Hill DV, Tirkes T. Advanced MR imaging of the pancreas. *Magn Reson Imaging Clin N Am*. 2020 Aug;28(3):353–367. doi: 10.1016/j.mric.2020.03.003. PMID: 32624154; PMCID: PMC8007215.
22. Expert Panel on Gastrointestinal Imaging, Fábrega-Foster K, Kamel IR, et al. ACR appropriateness criteria – pancreatic cyst. *J Am Coll Radiol*. 2020 May;17(5S):S198–S206. doi: 10.1016/j.jacr.2020.01.021. PMID: 32370963.
23. Parakh A, Tirkes T. Advanced imaging techniques for chronic pancreatitis. *Abdom Radiol (NY)*. 2020 May;45(5):1420–1438. doi: 10.1007/s00261-019-02191-0. PMID: 31428813; PMCID: PMC7028513.
24. Hart PA, Conwell DL. Chronic pancreatitis: Managing a difficult disease. *Am J Gastroenterol*. 2020 Jan;115(1):49–55. doi: 10.14309/ajg.0000000000000421. PMID: 31764092; PMCID: PMC6940526.
25. Megibow AJ, Baker ME, Morgan DE, et al. Management of incidental pancreatic cysts: A white paper of the ACR Incidental Findings Committee. *J Am Coll Radiol*. 2017 Jul;14(7):911–923. doi: 10.1016/j.jacr.2017.03.010. PMID: 28533111.
26. Palestro CJ, Abikhzer G, Bar-Sever Z, et al. Appropriate use criteria for the use of nuclear medicine in fever of unknown origin. Published 2023. Accessed July 1, 2024. <https://snmmi.org/Web/Clinical-Practice/Appropriate-Use-Criteria/Arti>

cles/Appropriate-Use-Criteria-for-the-Use-of-Nuclear-Medicine-in-Fever-of-Unknown-Origin.aspx.

27. Hess S, Noriega-Álvarez E, Leccisotti L, et al. EANM consensus document on the use of [18F]FDG PET/CT in fever and inflammation of unknown origin. *Eur J Nucl Med Mol Imaging*. 2024 Apr 27. doi: 10.1007/s00259-024-06732-8. Online ahead of print. PMID: 38676736.
28. Griffin N, Charles-Edwards G, Grant LA. Magnetic resonance cholangiopancreatography: The ABC of MRCP. *Insights Imaging*. 2012 Feb;3(1):11-21. doi: 10.1007/s13244-011-0129-9. PMID: 22695995; PMCID: PMC3292642.
29. Boraschi P, Donati F, Cervelli R, et al. Secretin-stimulated MR cholangiopancreatography: Spectrum of findings in pancreatic diseases. *Insights Imaging*. 2016 Dec;7(6):819-829. doi: 10.1007/s13244-016-0517-2. PMID: 27628744; PMCID: PMC5110475.
30. Expert Panel on Gastrointestinal Imaging, Arif-Tiwari H, Porter KK, et al. ACR appropriateness criteria - abnormal liver function tests. *J Am Coll Radiol*. 2023 Nov;20(11S):S302-S314. doi: 10.1016/j.jacr.2023.08.023. PMID: 38040457.
31. Expert Panel on Gastrointestinal Imaging, Hindman NM, Arif-Tiwari H, et al. ACR appropriateness criteria - jaundice. *J Am Coll Radiol*. 2019 May;16(5S):S126-S140. doi: 10.1016/j.jacr.2019.02.012. PMID: 31054739.
32. Chamokova B, Bastati N, Poetter-Lang S, et al. The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases. *Br J Radiol*. 2018 Apr;91(1084):20170677. doi: 10.1259/bjr.20170677. PMID: 29206061; PMCID: PMC5966000.
33. Giljaca V, Gurusamy KS, Takwoingi Y, et al. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography for common bile duct stones. *Cochrane Database Syst Rev*. 2015 Feb 26;2015(2):CD011549. doi: 10.1002/14651858.CD011549. PMID: 25719224; PMCID: PMC6464848.
34. Expert Panel on Gastrointestinal Imaging, Porter KK, Zaheer A, et al. ACR appropriateness criteria - acute pancreatitis. *J Am Coll Radiol*. 2019 Nov;16(11S):S316-S330. doi: 10.1016/j.jacr.2019.05.017. PMID: 31685100.

35. Kaltenthaler EC, Walters SJ, Chilcott J, et al. MRCP compared to diagnostic ERCP for diagnosis when biliary obstruction is suspected: A systematic review. *BMC Med Imaging*. 2006 Aug 14;6:9. doi: 10.1186/1471-2342-6-9. PMID: 16907974; PMCID: PMC1579209.
36. Wasser EJ, Prevedello LM, Sodickson A, Mar W, Khorasani R. Impact of a real-time computerized duplicate alert system on the utilization of computed tomography. *JAMA Intern Med*. 2013;173(11):1024-1026. doi: 10.1001/jamainternmed.2013.543. PMID: 23609029.
37. Expert Panel on Urological Imaging, Alexander LF, Oto A, et al. ACR appropriateness criteria – lower urinary tract symptoms, suspicion of benign prostatic hyperplasia. *J Am Coll Radiol*. 2019 Nov;16(11S):S378-S383. doi: 10.1016/j.jacr.2019.05.031. PMID: 31685105.
38. Hernando D, Zhang Y, Pirasteh A. Quantitative diffusion MRI of the abdomen and pelvis. *Med Phys*. 2022 Apr;49(4):2774-2793. doi: 10.1002/mp.15246. PMID: 34554579; PMCID: PMC8940741.
39. Staubli SM, Kettelhack C, Oertli D, et al. Efficacy of intraoperative cholangiography versus preoperative magnetic resonance cholangiography in patients with intermediate risk for common bile duct stones. *HPB (Oxford)*. 2022 Nov;24(11):1898-1906. doi: 10.1016/j.hpb.2022.05.1346. PMID: 35817694.
40. Suzuki M, Sekino Y, Hosono K, et al. Endoscopic ultrasound versus magnetic resonance cholangiopancreatography for the diagnosis of computed tomography-negative common bile duct stone: Prospective randomized controlled trial. *Dig Endosc*. 2022 Jul;34(5):1052-1059. doi: 10.1111/den.14193. PMID: 34784076.
41. Timmerhuis HC, van Dijk SM, Verdonk RC, et al. Various modalities accurate in diagnosing a disrupted or disconnected pancreatic duct in acute pancreatitis: A systematic review. *Dig Dis Sci*. 2021 May;66(5):1415-1424. doi: 10.1007/s10620-020-06413-0. PMID: 32594462; PMCID: PMC8053185.
42. Akisik MF, Jennings SG, Aisen AM, et al. MRCP in patient care: a prospective survey of gastroenterologists. *American Journal of Roentgenology*. 2013 Sep;201(3):573-7.

43. Sperna Weiland CJ, Verschoor EC, Poen AC, et al. Suspected common bile duct stones: reduction of unnecessary ERCP by pre-procedural imaging and timing of ERCP. *Surgical Endoscopy*. 2023 Feb;37(2):1194-202.
44. Razik A, Das CJ, Sharma S. Angiomyolipoma of the kidneys: current perspectives and challenges in diagnostic imaging and image-guided therapy. *Current problems in diagnostic radiology*. 2019 May 1;48(3):251-61.

Clinical Guideline Revision History/Information

Original Date: August 2, 2024		
Review History		
Version 2	10/30/2024	Edited repeat imaging criteria language.
Version 3	2/20/2025	Modified policy based on physician feedback to provide avenue to approval in the scenario where MRI/MRCP is the appropriate first-line imaging. Added references.